CITOMEGALOVIRUS: PRIČA O REZISTENCIJI
Sažetak
Citomegalovirus (CMV) je patogen koji inficira većinu svetske populacije. Pokazuje širok spektar kliničkih manifestacija, počevši od asimptomatske infekcije u zdravih osoba, preko kongenitalne bolesti novorođenčeta, sve do po život opasnih oboljenja u populaciji imunokompromitovanih. Pravovremeno započinjanje optimalne terapije može biti spasonosno po bolesnika. Citomegalovirus razvija rezistenciju na specifične antivirusne lekove, što u pojedinim slučajevima ima za posledicu nepovoljan ishod. U ovom mini preglednom radu biće sagledani molekularna etiologija i incidenca rezistencije, spektar dostupnih antivirusnih lekova, kao i dijagnostičke metode za otkrivanje rezistencije na ove supstance.
Reference
Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010 Oct; 23(4):689-712.
Knox GE. Cytomegalovirus: import of sexual transmission. Clin Obstet Gynecol. 1983 Mar; 26(1):173-177.
Chakravarty A, Kashyap B, Rathi K. The seroepidemiological study on cytomegalovirus in women of child bearing age with special reference to pregnancy and maternal-fetal transmission. Indian J Pathol Microbiol. 2005 Oct; 48(4):518-521.
Centres for Disease Control and Prevention. Cytomegalovirus (CMV) and Congenital CMV Infection. Available from: https://www.cdc.gov/cmv/overview.html [Accessed 5th October 2019].
Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am. 2010 Jun; 24(2):413–437.
Boeckh M, Fries B, Nichols WG. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant. 2004 Jun;8 Suppl 5:19-27.
Boeckh M, Ljungman P, 2009. How we treat CMV in hematopoietic cell transplant recipients. Blood. 2009 Jun; 113(23):5711-5719.
Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. 2000 Jan; 13(1):83-121.
Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant. 2008 Oct; 8(10):2111-2118.
Swanson EC, Schleiss MR. Congenital cytomegalovirus infection: new prospects for prevention and therapy. Pediatr Clin North Am. 2013 Apr; 60(2):335–349.
Stanojević M. Antivirusni lekovi. In: Savić B, Mitrović S, Jovanović T, editors. Medicinska mikrobiologija. Beograd, Srbija: Medicinski fakultet Univerziteta u Beogradu, CIBID; 2019. p.395.
Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis. 1997 Jul; 176(1):69–77.
Eckle T, Lang P, Prix L, Jahn G, Klingebiel T, Handgretinger R, et al. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant. 2002 Oct; 30(7):433-439.
Wolf DG, Yaniv I, Honigman A, Kassis I, Schonfeld T, Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis. 1998 Aug; 178(2):535-538.
Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002 Oct; 35(7):866–872.
Boivin G, Goyette N, Gilbert C, Covington E. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J Med Virol. 2005 Nov; 77(3):425-429.
Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004 May; 189(9):1615-1618.
Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009;14(5):697-704.
Prix L, Hamprecht K, Holzhüter B, Handgretinger R, Klingebiel T, Jahn G. Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J Infect Dis. 1999 Aug; 180(2):491-495.
Springer KL, Chou S, Li S, Giller RH, Quinones R, Shira JE, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol. 2005 Jan; 43(1):208-213.
Göhring K, Hamprecht K, Jahn G. Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. Comput Struct Biotechnol J. 2015 Feb; 13:153-9.
Blanco L, Bernad A, Blasco MA, Salas M. A general structure for DNA-dependent DNA polymerases. Gene. 1991 Apr; 100:27-38.
Cihlar T, Fuller MD, Mulato AS, Cherrington JM. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology. 1998 Sep; 248(2):382-393.
Hall JD, Orth KL, Sander KL, Swihart BM, Senese RA. Mutations within conserved motifs in the 3’-5’ exonuclease domain of herpes simplex virus DNA polymerase. J Gen Virol. 1995 Dec; 76(Pt 12):2999-3008.
Teo IA, Griffin BE, Jones MD. Characterization of the DNA polymerase gene of human herpesvirus 6. J Virol. 1991 Sep; 65(9):4670-4680.
Bauer DJ. A history of the discovery and clinical application of antiviral drugs. Br Med Bull. 1985 Oct; 41(4):309-14.
Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat. 2002 Apr; 5(2):88-114.
Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009; 4(5):e5512.
Crumpacker CS. Ganciclovir. N Engl J Med. 1996 Sep; 335(10):721-729.
Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994 Aug; 48(2):199-226.
Deray G, Martinez F, Katlama C, Levaltier B, Beaufils H, Danis M, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989;9(4):316-321.
De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 2003 Oct; 16(4):569-596.
Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol. 1997 Sep; 7(3):145-156.
Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 1997 Oct; 176(4):892-898.
Akhter K. Cytomegalovirus (CMV) Treatment & Management. Available from: https://emedicine.medscape.com/article/215702-treatment [Accessed: Accessed 5th October 2019].
Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis. 2002 Jan; 185(2):162-169.
Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis. 2003 Jul; 188(1):32-39.
Chou S, Marousek G, Parenti DM, Gordon SM, LaVoy AG, Ross JG, et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis. 1998 Aug; 178(2):526-530.
Scott GM, Weinberg A, Rawlinson WD, Chou S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother. 2007 Jan; 51(1):89-94.
Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis. 2000 Dec; 182(6):1765-1768.
Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis. 1997 Sep; 176(3):786-9.